Skip to main content
Back to News
Converge Bio raised 25 million dollars in Series A funding led by Bessemer, bringing its total finan...
Funding
1 min read
IL

Converge Bio raised 25 million dollars in Series A funding led by Bessemer, bringing its total finan...

The AMW Read

Updates the player map for the Vertical AI โ€” Healthcare/Bio segment with a successful Series A for a protein manufacturing/antibody discovery platform.
NoveltySignificance
Healthcare & Bio ยท Player Map

Converge Bio raised 25 million dollars in Series A funding led by Bessemer, bringing its total financing to 30 million dollars. ๐Ÿš€ The platform has completed 40 programs, achieving 4 to 7 times higher protein manufacturing yields and discovering antibodies with single-digit nanomolar binding affinities. By integrating multiple models into a single system, they allow biologists to work without writing code. ๐Ÿงฌ This shift from trial-and-error to high-velocity AI systems represents a systemic leap for oncology and neurodegenerative R&D. ๐Ÿ”ฌ

#AI #DrugDiscovery #Biotech #Funding #GenerativeAI

How This Connects

Based on Healthcare & Bio ยท Player Map

  1. 4d agoInnovaccer acquires CaduceusHealth to expand AI-led revenue cycle managementInnovaccer
  2. 1w agoIsomorphic Labs raises $2.1B led by Thrive Capital in largest AI drug-discovery roundIsomorphic Labs
  3. 3w agoOpenAI model outperforms doctors in ER diagnoses, achieving 67% accuracy vs 55%OpenAI
  4. 1mo agoOpenAI Launches GPT-Rosalind, a Specialized Frontier Model for Life Sciences Research and Drug DiscoveryOpenAI
  5. 4mo agoConverge Bio raised 25 million dollars in Series A funding led by Bessemer, bringing its total finan... ยท THIS ARTICLE

Related News

More news from Converge Bio

Stay updated with the latest news and announcements from Converge Bio.

View all Converge Bio news

Discover AI Startups

Explore 2,000+ AI companies with VC-grade analysis, funding data, and investment insights.

Explore Dashboard